The peroxisome proliferator-activated receptor agonist pioglitazone and 5-lipoxygenase inhibitor zileuton have no effect on lung inflammation in healthy volunteers by positron emission tomography in a single-blind placebo-controlled cohort study.
BACKGROUND:Anti-inflammatory drug development efforts for lung disease have been hampered in part by the lack of noninvasive inflammation biomarkers and the limited ability of animal models to predict efficacy in humans. We used 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in...
Main Authors: | Delphine L Chen, Howard J Huang, Derek E Byers, Adrian Shifren, Bryan Belikoff, Jacquelyn T Engle, Elizabeth Arentson, Debra Kemp, Sharon Phillips, David E Scherrer, Hideji Fujiwara, Katherine J Spayd, Frank J Brooks, Richard A Pierce, Mario Castro, Warren Isakow |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5802889?pdf=render |
Similar Items
-
New Zileuton-Hydroxycinnamic Acid Hybrids: Synthesis and Structure-Activity Relationship towards 5-Lipoxygenase Inhibition
by: Audrey Isabel Chiasson, et al.
Published: (2020-10-01) -
Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation.
by: Elias Gounaris, et al.
Published: (2015-01-01) -
The 5-Lipoxygenase Inhibitor Zileuton Protects Pressure Overload-Induced Cardiac Remodeling via Activating PPARα
by: Qing-Qing Wu, et al.
Published: (2019-01-01) -
Inhibition of 5-Lipoxygenase inhibitor zileuton in high-fat diet-induced nonalcoholic fatty liver disease progression model
by: Kuifen Ma, et al.
Published: (2017-11-01) -
Zileuton, a 5-Lipoxygenase Inhibitor, Exerts Anti-Angiogenic Effect by Inducing Apoptosis of HUVEC via BK Channel Activation
by: Hyun-Joung Lim, et al.
Published: (2019-09-01)